Today: 30 June 2026
Browse Category

NYSE:AMH 9 January 2026 - 21 January 2026

Blackstone stock in focus after $5 billion Beacon Offshore talks, Trump housing order

Blackstone stock in focus after $5 billion Beacon Offshore talks, Trump housing order

New York, Jan 21, 2026, 08:39 EST — Premarket Blackstone Inc is exploring a sale of Beacon Offshore Energy for over $5 billion, according to a source familiar with the situation. Earlier Tuesday, Bloomberg News reported the firm had started preliminary talks with banks about a possible IPO as soon as the first quarter. Shares of Blackstone dropped 5.9% to $153.91 in Tuesday’s trading.
21 January 2026
··
Opendoor stock pops after Trump targets big homebuyers as CEO insists firm “doesn’t hold the homes”

Opendoor stock pops after Trump targets big homebuyers as CEO insists firm “doesn’t hold the homes”

Opendoor Technologies shares rose Thursday after CEO Kaz Nejatian dismissed worries from investors over President Donald Trump’s plan to crack down on large institutional homebuyers. “We’re not institutional investors … We don’t hold the homes!” Nejatian insisted. https://www.tradingview.com/news/stockstory:ea2657819094b:0-opendoor-open-shares-skyrocket-what-you-need-to-know/ The rebound is significant because Trump’s housing message has already started shifting investments within the sector, even though Washington has provided few details. Trump said he was “immediately taking steps” to stop large institutions from buying more single-family homes and called on Congress to make the ban official, adding: “People live in homes, not corporations.” https://www.cbsnews.com/news/trump-ban-institutional-investors-single-family-homes/
9 January 2026
·····

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Go toTop